Clinical Trial: Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis
Brief Summary: Necrotizing enterocolitis (NEC) is a serious gastrointestinal disorder that primarily affects preterm infants. About 10% of babies less than 32 weeks gestation at birth will develop it. Overall, 30% of babies who develop NEC will die from it, with many others developing long term gastrointestinal problems. The most important factor in its development is a premature intestinal tract. Epidermal growth factor (EGF) is an important growth factor in the development and maintenance of the gastrointestinal tract. This study will look for a relationship between EGF levels in premature babies and the development of NEC.
Detailed Summary:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Dates:
Date Received: April 25, 2003
Date Started:
Date Completion:
Last Updated: January 12, 2010
Last Verified: January 2010